Literature DB >> 29169110

Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change.

Yang Liu1, Jianping Li1, Jingao Yu1, Yingyi Wang1, Jingbo Lu1, Er-Xin Shang1, Zhenhua Zhu1, Jianming Guo2, Jinao Duan3.   

Abstract

Chronic kidney disease (CKD) is a worldwide public health problem. Uremic retention solutes such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS) are accumulated in CKD patients and are associated with the incidence of CKD progression. Amino acids are the major precursors of uremic retention solutes in gut. The dynamic change of amino acid metabolism in the gut during CKD progression has not been reported previously. In this paper, we studied the dynamic change of gut IS/PCS precursor and amino acid metabolism profile during CKD progression in 5/6 nephrectomized (5/6Nx) rats model. The related gut microbiota and metagenome profile was also studied. Rat plasma, urine and feces were collected at different time points after nephrectomization. Plasma IS and PCS, fecal indole (the precursor of IS), p-cresol (the precursor of PCS) and 19 kinds of amino acids were analyzed by LC-MS. During CKD progression, 5/6 Nx rats showed increased plasma IS, PCS concentration and increased fecal indole, p-cresol concentration. 5/6 Nx rats also showed disordered gut amino acids metabolism profile which became more significant along with the progession of CKD. The abundance of some specific gut bacteria also changed significantly in 5/6 Nx rats. The 16S rDNA sequencing data of gut microbiota was further analyzed by an online tool PICRUSt, a large-scale computational method for metagenomes prediction with 16S rDNA sequencing data. The content of each gene was compared between the two groups by Mann-Whitney U test, and then the significantly regulated genes in 5/6 Nx group were subjected to KEGG website. The amino acid metabolism related genes were picked out. Most of these genes are more abundant in 5/6 Nx groups. Our study showed that gut amino acids metabolism profile was disordered with CKD progression, which was highly related to the gut microbiota dysbiosis and metagenome change. And that regulation of gut amino acids metabolism pathway may be a possible way to intervene the progression of CKD.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amino acid; Chronic kidney disease; Gut microbiota; Metagenomes prediction

Mesh:

Substances:

Year:  2017        PMID: 29169110     DOI: 10.1016/j.jpba.2017.11.040

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  15 in total

1.  Oral and intravenous iron treatment alter the gut microbiome differentially in dialysis patients.

Authors:  Huan Liu; Wenqi Wu; Yankun Luo
Journal:  Int Urol Nephrol       Date:  2022-09-27       Impact factor: 2.266

2.  Yishen Qingli Heluo Granule Ameliorates Renal Dysfunction in 5/6 Nephrectomized Rats by Targeting Gut Microbiota and Intestinal Barrier Integrity.

Authors:  Xian Sun; Jie Chen; Yiting Huang; Sha Zhu; Shuaishuai Wang; Zijing Xu; Junfeng Zhang; Wei Sun
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

Review 3.  Microbiome and Cardiovascular Disease in CKD.

Authors:  Anna Jovanovich; Tamara Isakova; Jason Stubbs
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-09       Impact factor: 8.237

Review 4.  Plant-Based Diets, the Gut Microbiota, and Trimethylamine N-Oxide Production in Chronic Kidney Disease: Therapeutic Potential and Methodological Considerations.

Authors:  Gretchen N Wiese; Annabel Biruete; Ranjani N Moorthi; Sharon M Moe; Stephen R Lindemann; Kathleen M Hill Gallant
Journal:  J Ren Nutr       Date:  2020-06-29       Impact factor: 3.655

5.  Qi-Deficiency Related Increases in Disease Susceptibility Are Potentially Mediated by the Intestinal Microbiota.

Authors:  Ke Ma; Jieyu Chen; Liuyan Kuang; Jianlu Bi; Jingru Cheng; Fei Li; Xiaomin Sun; Xiaoli Nie; Yanyan Liu; Ren Luo; Xiaoshan Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-23       Impact factor: 2.629

6.  Intestinal flora alterations in patients with early chronic kidney disease: a case-control study among the Han population in southwestern China.

Authors:  Qiongdan Hu; Kaiyan Wu; Wei Pan; Yan Zeng; Keqin Hu; Dingguo Chen; Xinchun Huang; Qiong Zhang
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

7.  Preliminary evaluation of fecal fatty acid concentrations in cats with chronic kidney disease and correlation with indoxyl sulfate and p-cresol sulfate.

Authors:  Stacie Summers; Jessica M Quimby; Robert Kyle Phillips; Jonathan Stockman; Anitha Isaiah; Jonathan A Lidbury; Joerg M Steiner; Jan Suchodolski
Journal:  J Vet Intern Med       Date:  2019-11-06       Impact factor: 3.333

8.  Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD.

Authors:  Cassandra Kimber; Shiqin Zhang; Cassandra Johnson; Raymond E West; Alexander J Prokopienko; Jonathan D Mahnken; Alan S Yu; Andrew N Hoofnagle; Diana Ir; Charles E Robertson; Makoto Miyazaki; Michel Chonchol; Anna Jovanovich; Bryan Kestenbaum; Daniel N Frank; Thomas D Nolin; Jason R Stubbs
Journal:  Kidney360       Date:  2020-11-25

Review 9.  Role of gut microbiota in identification of novel TCM-derived active metabolites.

Authors:  Tzu-Lung Lin; Chia-Chen Lu; Wei-Fan Lai; Ting-Shu Wu; Jang-Jih Lu; Young-Mao Chen; Chi-Meng Tzeng; Hong-Tao Liu; Hong Wei; Hsin-Chih Lai
Journal:  Protein Cell       Date:  2020-09-15       Impact factor: 14.870

10.  Multi-Solvent Extraction Procedure for the Pioneer Fecal Metabolomic Analysis-Identification of Potential Biomarkers in Stable Kidney Transplant Patients.

Authors:  Soumaya Kouidhi; Nessrine Souai; Muhanad Alhujaily; Oumaima Zidi; Ameni Kochbati; Alaeddine Redissi; Tareg M Belali; Imene El Kossai; Jamelddine El Manaa; Ameur Cherif; Wissem Mnif; Amor Mosbah
Journal:  Diagnostics (Basel)       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.